Opioid-Induced Constipation (OIC)-Pipeline Review, H2 2015

Opioid-Induced Constipation (OIC)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7006IDB
  • |
  • Pages: 76
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Opioid-Induced Constipation (OIC)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Opioid-Induced Constipation (OIC)-Pipeline Review, H2 2015', provides an overview of the Opioid-Induced Constipation (OIC)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Opioid-Induced Constipation (OIC) Overview 7

Therapeutics Development 8

Pipeline Products for Opioid-Induced Constipation (OIC)-Overview 8

Opioid-Induced Constipation (OIC)-Therapeutics under Development by Companies 9

Opioid-Induced Constipation (OIC)-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Opioid-Induced Constipation (OIC)-Products under Development by Companies 12

Opioid-Induced Constipation (OIC)-Companies Involved in Therapeutics Development 13

AstraZeneca Plc 13

Cosmo Pharmaceuticals S.p.A 14

Ironwood Pharmaceuticals, Inc. 15

Shionogi & Co., Ltd. 16

Sucampo Pharmaceuticals, Inc. 17

Synergy Pharmaceuticals, Inc. 18

Valeant Pharmaceuticals International, Inc. 19

Opioid-Induced Constipation (OIC)-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Combination Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

(axelopran sulfate + oxycodone hydrochloride)-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

axelopran sulfate-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

dolcanatide-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

linaclotide-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

lubiprostone-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

methylnaltrexone bromide-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

naldemedine-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

naloxegol oxalate-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

naloxone hydrochloride-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Opioid-Induced Constipation (OIC)-Recent Pipeline Updates 47

Opioid-Induced Constipation (OIC)-Dormant Projects 67

Opioid-Induced Constipation (OIC)-Discontinued Products 68

Opioid-Induced Constipation (OIC)-Product Development Milestones 69

Featured News & Press Releases 69

Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 69

Jun 24, 2015: Shionogi Announces That Naldemedine Met the Primary Endpoint in Its First Japanese Phase 3 Study for the Treatment of Opioid-Induced Constipation in Cancer Patients 69

Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation 69

May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 70

May 16, 2015: MOVANTIK (naloxegol) Safety Analyses of Opioid-Induced Constipation Patients 65 and Older with Chronic Non-Cancer Pain 70

May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week 72

Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 72

Apr 02, 2015: Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca 73

Mar 31, 2015: MOVANTIK (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US 73

Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 74

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Late Stage Development, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Opioid-Induced Constipation (OIC)-Pipeline by AstraZeneca Plc, H2 2015 13

Opioid-Induced Constipation (OIC)-Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015 14

Opioid-Induced Constipation (OIC)-Pipeline by Ironwood Pharmaceuticals, Inc., H2 2015 15

Opioid-Induced Constipation (OIC)-Pipeline by Shionogi & Co., Ltd., H2 2015 16

Opioid-Induced Constipation (OIC)-Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015 17

Opioid-Induced Constipation (OIC)-Pipeline by Synergy Pharmaceuticals, Inc., H2 2015 18

Opioid-Induced Constipation (OIC)-Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 19

Assessment by Monotherapy Products, H2 2015 20

Assessment by Combination Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 23

Number of Products by Stage and Mechanism of Action, H2 2015 25

Number of Products by Stage and Route of Administration, H2 2015 27

Number of Products by Stage and Molecule Type, H2 2015 29

Opioid-Induced Constipation (OIC) Therapeutics-Recent Pipeline Updates, H2 2015 47

Opioid-Induced Constipation (OIC)-Dormant Projects, H2 2015 67

Opioid-Induced Constipation (OIC)-Discontinued Products, H2 2015 68

List of Figures

Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Late Stage Development, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Top 10 Targets, H2 2015 22

Number of Products by Stage and Top 10 Targets, H2 2015 22

Number of Products by Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Top 10 Routes of Administration, H2 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26

Number of Products by Top 10 Molecule Types, H2 2015 28

Number of Products by Stage and Top 10 Molecule Types, H2 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca Plc

Cosmo Pharmaceuticals S.p.A

Ironwood Pharmaceuticals, Inc.

Shionogi & Co., Ltd.

Sucampo Pharmaceuticals, Inc.

Synergy Pharmaceuticals, Inc.

Valeant Pharmaceuticals International, Inc.

Opioid-Induced Constipation (OIC) Therapeutic Products under Development, Key Players in Opioid-Induced Constipation (OIC) Therapeutics, Opioid-Induced Constipation (OIC) Pipeline Overview, Opioid-Induced Constipation (OIC) Pipeline, Opioid-Induced Constipation (OIC) Pipeline Assessment

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com